Dokumentenart: | Artikel | ||||
---|---|---|---|---|---|
Titel eines Journals oder einer Zeitschrift: | Therapeutic Drug Monitoring | ||||
Verlag: | Lippincott | ||||
Ort der Veröffentlichung: | PHILADELPHIA | ||||
Band: | 43 | ||||
Nummer des Zeitschriftenheftes oder des Kapitels: | 2 | ||||
Seitenbereich: | S. 264-270 | ||||
Datum: | April 2021 | ||||
Institutionen: | Medizin > Lehrstuhl für Anästhesiologie Medizin > Lehrstuhl für Innere Medizin II Medizin > Lehrstuhl für Medizinische Mikrobiologie und Hygiene Chemie und Pharmazie > Institut für Pharmazie > Arbeitsgruppe Klinische Pharmazie (Dr. Dorn) | ||||
Identifikationsnummer: |
| ||||
Stichwörter / Keywords: | ceftazidime; meropenem; piperacillin; flucloxacillin; ultrafiltration | ||||
Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin 600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie | ||||
Status: | Veröffentlicht | ||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||
An der Universität Regensburg entstanden: | Ja | ||||
Dokumenten-ID: | 43963 |
Zusammenfassung
Background: The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients. Methods: Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or ...
Zusammenfassung
Background:
The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients.
Methods:
Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or flucloxacillin (FXN) by continuous infusion. Up to 2 arterial blood samples were drawn at steady state. Patients could be included more than once if they received another antibiotic. Free drug concentrations were determined by high-performance liquid chromatography with ultraviolet detection after ultrafiltration, using a method that maintained physiological conditions (pH 7.4/37 degrees C). Total drug concentrations were determined to calculate the unbound fraction. In a post-hoc analysis, free concentrations were compared with the target value of 4x the epidemiological cut-off value (ECOFF) for Pseudomonas aeruginosa as a worst-case scenario for empirical therapy with CAZ, MEM or PIP/tazobactam and against methicillin-sensitive Staphylococcus aureus for targeted therapy with FXN.
Results:
Fifty different antibiotic treatment periods in 38 patients were evaluated. The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function. The mean unbound fractions (fu) of CAZ, MEM, and PIP were 102.5%, 98.4%, and 95.7%, with interpatient variability of fu of FXN was 11.6%, with interpatient variability of 39%. It was observed that 2 of 12 free concentrations of CAZ, 1 of 40 concentrations of MEM, and 11 of 23 concentrations of PIP were below the applied target concentration of 4 x ECOFF for P. aeruginosa. All concentrations of FXN (9 samples from 6 patients) were >8 x ECOFF for methicillin-sensitive Staphylococcus aureus.
Conclusions:
For therapeutic drug monitoring purposes, measuring total or free concentrations of CAZ, MEM, or PIP is seemingly adequate. For highly protein-bound beta-lactams such as FXN, free concentrations should be favored in ICU patients with prevalent hypoalbuminemia.
Metadaten zuletzt geändert: 30 Jul 2024 06:57